Valuation: Talphera, Inc.

Market Cap 64.87M 56.75M 52.33M 48.42M 91.91M 6.19B 93.45M 627M 246M 3.04B 244M 238M 10.53B P/E 2026 *
-5.44x
P/E 2027 * -4.86x
Enterprise Value 64.87M 56.75M 52.33M 48.42M 91.91M 6.19B 93.45M 627M 246M 3.04B 244M 238M 10.53B EV / Sales 2026 *
-
EV / Sales 2027 * 324x
Free-Float
78.58%
Yield 2026 *
-
Yield 2027 * -
1 day+8.80%
1 week+29.52%
Current month+32.04%
1 month+60.60%
3 months+72.15%
6 months+24.77%
Current year+19.30%
1 week 1
Extreme 1
1.36
1 month 0.8
Extreme 0.8
1.36
Current year 0.69
Extreme 0.6866
1.36
1 year 0.38
Extreme 0.38
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
31
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 2017-03-05
Director of Finance/CFO 56 2017-07-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 60 2006-07-31
Director/Board Member 72 2010-01-31
Chairman 75 2013-02-10
Date Insider Type Main position Quantity % Market Cap.
06-21Free

Director

35,800 0.0715%
06-21Free

Director

35,800 0.0715%
06-21Free

Director

35,800 0.0715%
Change 5-day change 1-year change 3-year change Capi.($)
+8.80%+29.52%+179.09%+4.62% 64.87M
-0.73%-0.24%+53.71%+14.74% 311B
+0.32%-3.39%+25.09%-4.71% 68.98B
-2.18%+2.09%+40.90%+114.69% 9.53B
-0.21%+4.27%+6.96%+1.89% 8.62B
-2.31%-7.50%-13.48%+6.37% 4.26B
+4.55%-4.61%+15.19%+24.63% 3.83B
-2.46%-4.40%-36.65%+24.81% 3.41B
-3.35%+2.83%+51.92%+64.47% 2.93B
+0.28%-6.94%+9.56%-24.42% 2.08B
Average +0.28%+0.39%+33.23%+22.71% 41.49B
Weighted average by Cap. -0.52%-0.40%+45.68%+13.78%

Financials

2026 *2027 *
Net sales - 200K 175K 161K 149K 283K 19.09M 288K 1.93M 757K 9.37M 751K 735K 32.47M
Net income -17.96M -15.72M -14.49M -13.41M -25.45M -1.71B -25.88M -174M -68.03M -842M -67.44M -65.98M -2.92B -20.15M -17.62M -16.25M -15.04M -28.54M -1.92B -29.02M -195M -76.29M -944M -75.63M -73.99M -3.27B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
26-07-09 US$1.360 +8.80% 1,088,696
26-07-08 US$1.250 +5.04% 863,908
26-07-07 US$1.190 +0.85% 770,731
26-07-06 US$1.180 +10.28% 874,786
26-07-02 US$1.070 +1.90% 427,101
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.250USD
Average target price
3.167USD
Spread / Average Target
+153.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock